• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Johnson & Johnson

    9/4/25 2:37:23 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JNJ alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001745938
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    JOHNSON & JOHNSON
    SEC File Number
    001-03215
    Address of Issuer
    ONE JOHNSON & JOHNSON PLZ
    NEW BRUNSWICK
    NEW JERSEY
    08933
    Phone
    732-524-2455
    Name of Person for Whose Account the Securities are To Be Sold
    Taubert Jennifer L
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    5647110040904.33240833887209/04/2025
    NYSE


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common09/04/2025Option Granted - 02/08/2016IssuerCheckbox not checked5647109/04/2025Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    09/04/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Jennifer L Taubert

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $JNJ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JNJ

    DatePrice TargetRatingAnalyst
    7/23/2025Hold → Buy
    Erste Group
    5/13/2025$153.00Outperform → Market Perform
    Leerink Partners
    12/10/2024$166.00Neutral
    BofA Securities
    11/15/2024$190.00Outperform
    Wolfe Research
    7/23/2024$160.00 → $150.00Outperform → Neutral
    Daiwa Securities
    5/30/2024$160.00Neutral
    Goldman
    4/18/2024$170.00Hold → Buy
    HSBC Securities
    12/13/2023$170.00 → $163.00Overweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $JNJ
    SEC Filings

    View All

    SEC Form 144 filed by Johnson & Johnson

    144 - JOHNSON & JOHNSON (0000200406) (Subject)

    9/4/25 2:37:23 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form N-PX filed by Johnson & Johnson

    N-PX - JOHNSON & JOHNSON (0000200406) (Filer)

    8/26/25 4:27:56 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Johnson & Johnson

    144 - JOHNSON & JOHNSON (0000200406) (Subject)

    8/15/25 3:57:38 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Johnson & Johnson upgraded by Erste Group

    Erste Group upgraded Johnson & Johnson from Hold to Buy

    7/23/25 8:55:43 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Johnson & Johnson from Outperform to Market Perform and set a new price target of $153.00

    5/13/25 8:56:13 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities resumed coverage on Johnson & Johnson with a new price target

    BofA Securities resumed coverage of Johnson & Johnson with a rating of Neutral and set a new price target of $166.00

    12/10/24 8:28:42 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive VP, General Counsel Forminard Elizabeth exercised 11,521 shares at a strike of $115.67 and covered exercise/tax liability with 9,570 shares, increasing direct ownership by 18% to 12,853 units (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    9/3/25 5:13:57 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and Chairman of the Board Duato Joaquin exercised 125,824 shares at a strike of $101.87 and sold $22,548,655 worth of shares (125,824 units at $179.21) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    8/25/25 7:12:16 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exec VP, CFO Wolk Joseph J exercised 16,820 shares at a strike of $101.87 and sold $2,975,571 worth of shares (16,820 units at $176.91) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    8/18/25 6:19:14 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    12/12/24 5:27:36 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results

    Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 14th to review third-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay o

    9/3/25 4:29:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Unveils Results from the VARIPURE Substudy of SECURE, a Real-World Study on VARIPULSE™ Platform, at 2025 European Society of Cardiology (ESC) Congress

    VARIPURE demonstrated strong safety outcomes with no incidence of stroke and 99.7% acute effectiveness of the VARIPULSE™ Platform in nearly 800 enrolled patientsi IRVINE, Calif., Sept. 2, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) -- Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, today announced acute safety and effectiveness results from the VARIPURE substudy of SECURE, evaluating the VARIPULSE™ Platform in pulsed field ablation (PFA) procedures for atrial fibrillation (AF). The real-world data, presented at the 2025 European Society of Cardiology (ESC) Congress in Madrid, demonstrated a strong safety profile, high acute effectiveness and procedural effic

    9/2/25 8:00:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New Data from the DanGer Shock Randomized Control Trial, Published in The New England Journal of Medicine, Confirms the Long-Term Survival Benefit of the Impella CP Heart Pump

    MADRID, Aug. 31, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) – Late breaking clinical science data, presented at the European Society of Cardiology (ESC) Congress today and simultaneously published in the New England Journal of Medicine (NEJM), finds at up to 10 years, when compared to standard care, routine use of Impella CP® in patients who have had a heart attack with cardiogenic shock leads to an absolute mortality reduction of 16.3% (95% CI: 0.54 to 0.92)1. When compared to the control arm at 10 years, Impella CP patients gained an average of 600 additional days alive (95% CI: 235 – 966 days)1.

    8/31/25 12:15:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 21, 2023 - FDA Roundup: July 21, 2023

    For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

    7/21/23 4:02:23 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

    For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

    5/5/22 4:51:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

    For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

    8/18/21 1:06:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Leadership Updates

    Live Leadership Updates

    View All

    Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

    Johnson & Johnson (NYSE:JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610707025/en/ "We are thrilled to have Daniel join Johnson & Johnson's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is an exceptional leader with deep financial expertise and understanding of global capital markets. Daniel's unique perspective and wealth of experience will be a tremendous asset to Johnson & Johnson as we continue to invest in and advance the next generation of healthcare inno

    6/10/25 4:51:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

    WARREN, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, today announced the appointment of David E. Banko, CPA, a leading expert with three decades of industry experience in market access and health policy, to its leadership team as Global Head of Government Affairs and Patient Access. In this critical role, Mr. Banko will spearhead market access strategies in collaboration with R&D across Tevogen's growing product portfolio in oncology, virology, neurology, and rheumatology to advance and support commercial readines

    3/25/25 1:11:06 PM ET
    $JNJ
    $TVGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor Relations

    Jessica Moore Appointed Group Chief Financial Officer, Johnson & Johnson, Innovative Medicine Johnson & Johnson (NYSE:JNJ) (the "Company") today announced the appointment of Darren Snellgrove to Vice President, Investor Relations. Jessica Moore, who has served as Vice President, Investor Relations since 2021, will assume the role of Group Chief Financial Officer, Johnson & Johnson, Innovative Medicine. The new appointments are effective May 1, 2025, and Mr. Snellgrove as well as Ms. Moore, will continue to report to Johnson & Johnson's Executive Vice President and Chief Financial Officer, Joseph Wolk. "Today's announcement reflects the deep bench of talent within Johnson & Johnson as well

    3/4/25 4:15:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Financials

    Live finance-specific insights

    View All

    Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results

    Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 14th to review third-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay o

    9/3/25 4:29:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2025

    Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2025 of $1.30 per share on the company's common stock. The dividend is payable on September 9, 2025 to shareholders of record at the close of business on August 26, 2025. The ex-dividend date is August 26, 2025. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely po

    7/16/25 6:25:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Reports Q2 2025 Results; Raises 2025 Outlook

    2025 Second-Quarter reported sales growth of 5.8% to $23.7 Billion with operational growth of 4.6%* and adjusted operational growth of 3.0%* 2025 Second-Quarter reflects earnings per share (EPS) of $2.29 and adjusted EPS of $2.77 Significant new product pipeline progress including approval of IMAAVY for generalized myasthenia gravis, priority review for TAR-200, data for CARVYKTI overall survival and progression-free benefits in multiple myeloma, and continuation of the clinical trial for a general surgery robotic system, OTTAVA Strong operational performance and favorable foreign exchange results in Company increasing full year estimated reported sales5 guidance at the midpoint b

    7/16/25 6:20:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Johnson & Johnson

    SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)

    4/10/24 5:12:55 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

    SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

    2/13/24 5:07:58 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

    SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

    1/30/24 12:46:49 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care